2014 Partnership Hub Report

Catalyzing Partnershipsfor Global Health

WIPO Re:Search Database Contribution - Sano�: Pentamidine samples for R&D (ID: 1341)

Annual ReportOpening Letter

Jennifer DentPresident, BVGH

1

Dear WIPO Re:Search Members and Friends,

I am proud of what has been accomplished in WIPO Re:Search over the past year and since its launch in October 2011. The Consortium was established to accelerate the development of drugs, vaccines, and diagnostics for malaria, tuberculosis, and neglected tropical diseases (NTDs) through collaborative research endeavors. At the close of 2014, 82 collaborations were in place between Members, including 38 established in 2014. A number of these collaborations have already obtained promising results, thus demonstrating the successful platform and potential impact of WIPO Re:Search.

As we embark on the fourth year of WIPO Re:Search, WIPO and

Members during and around the Annual Meeting. Our aim is to continue to provide a platform and partnering approach that meets the needs of Members while advancing the development of much needed products for neglected infectious diseases.

Throughout 2014, Members remained committed to the Consortium’s mission, eagerly sharing their assets, expertise, and ideas with one another. BVGH and WIPO were pleased to welcome Merck KGaA to WIPO Re:Search in 2014. We are excited by what Merck KGaA and our founding company Members, Alnylam, Eisai,

to research partnerships in 2015 and beyond. Examples of the founding company Members’ contributions to the WIPO Re:Search Database are highlighted throughout this report.

BVGH will continue to proactively engage Members and suggest unique partnerships in 2015. Now that several WIPO Re:Search

on identifying new partners who can contribute needed assets and expertise to ensure that these projects continue to move forward.

We are encouraged by the achievements WIPO Re:Search and its Members have had to date and we look forward to what will be accomplished in 2015. From all of us at BVGH, we are proud to be your partner in the joint mission to erase the burden that malaria, tuberculosis, and NTDs have on individuals across the globe.

The following report summarizes and describes BVGH’s key deliverables and accomplishments from 2014.

2014Partnering Objectives

and Achievements

*Diarrheal diseases not included in the list of qualifying WIPO Re:Search diseases; **Fungal disease, polio, RSV, multiple diseases

2

More and more, the global health community is embracing cross-sector collaborations as a critical element to ensure the expedient

development of products for neglected diseases. Now in its fourth year, WIPO Re:Search continues to establish meaningful cross-sector collaborations focused on developing products for these devastating diseases. In 2014, BVGH established 38 agreements between Members, bringing the total number of WIPO Re:Search agreements to 82. These 38 agreements spanned 13 diseases and involved 38 Members from 11 countries.

Malaria and tuberculosis continue to have the most agreements, with 44% of the partnerships established in 2014 and to date involving these two diseases. Other collaborations cover an additional 12 neglected diseases, including one new disease (neurocysticercosis) added in 2014. Drug discovery continued to be the primary focus of agreements established in 2014, and similar to past years, these agreements primarily involved sharing compounds to be screened.

BVGH continued to seek out new collaboration opportunities. By the end of 2014, 27 projects were in early-stage discussions between Members and 14 projects were in advanced negotiations.

BVGH’s objective was to establish 15 new agreements in 2014, which it far surpassed with 38 established over the year.

Partnering acrossthe globe

WIPO Re:Search Database Contribution - Alnylam: Intellectual property and know-how supporting Alnylam’s RNA interference (RNAi) platform technology (ID: 1362)

Drug (54)Diagnostic (14)Basic research (11)Vaccine/Adjuvant (3)

Human African trypanosomiasis (5)

Buruli ulcer (2)Chagas disease (6)

Diarrheal diseases (6)*Dengue (8)

Filarial diseases (5)Soil-transmitted helminthiases (7)

Malaria (22)Leishmaniasis (6)

Other (5)**

Tuberculosis (14)Schistosomiasis (9)

Neurocysticercosis (1)

*Diarrheal diseases not included in the list of qualifying WIPO Re:Search diseases; **Fungal disease, polio, RSV, multiple diseases

3

2014Partnering Objectives

and Achievements

4

While several Members have substan-tially leveraged WIPO Re:Search to advance their research goals, BVGH strives to encourage all Members to

explore and participate in collaborations.

Fifteen of the 38 Members participating in an agreement established in 2014 had not participated in a WIPO Re:Search collaboration before. A total of 49 Members have participated in a WIPO Re:Search partnership to date. Every single one of our 76 User and/or Provider Members has assets or research programs that could potentially be translated or incorporated into a product for a neglected disease. Thus it is BVGH’s continuing mission to ensure that

opportunities to participate and contribute to WIPO Re:Search.

The WIPO Re:Search consortium was established

access to industry assets. During 2012-2013 the majority of collaborations indeed involved

founding company Member. However, in 2014 this paradigm shifted. Sixty-six percent of new

neewteb stnemeerga devlovni spihsrentrap

Researchagreements

0 5 10 15 20 25

Malaria

Tuberculosis

Schistosomiasis

Dengue

Soil-transmitted helminthiases

Other

Diarrheal disease

Chagas disease

Leishmaniasis

Human African trypanosomiasis

Onchocerciasis

Buruli ulcer

Neurocysticercosis

Lymphatic �lariasis

2012

2014

2013

WIPO Re:Search Agreements by Disease

0 5 10 15 20 25 30 35 40 45 50 55

Drug

DiagnosticBasic research

Adjuvant/Vaccine

WIPO Re:Search Agreements by Product

Academic + Industry Industry + IndustryAcademic + Academic

2012 2013 2014

WIPO Re:Search Agreements by Partner

2012

2014

2013

WIPO Re:Search Database Contribution - Novartis: Novartis-GNF Malaria Box Dataset - hits from Plasmodium falciparum whole-cell screens (ID: 1861)

5

2014Recruitment Objectives

and Achievements

6

The output and impact of WIPO Re:Search correlates with the number of active User and/or Provider Members. Each Member brings a diverse set of skills,

expertise, interests, and assets that are integral to the success of the Consortium. To ensure a

BVGH continued to recruit new User Members in 2014. Fourteen new User Members joined WIPO Re:Search in 2014, including six developing world institutions. BVGH thus achieved its 2014 objective to recruit at least ten new User Members.

Financial stability and growth is critical to ensure that BVGH has the resources to engage Members, establish new partnerships, and support advancing collaborative research projects. In 2014 two new Funding Members joined WIPO Re:Search. In addition, BVGH

company Members of their continued commitment to WIPO Re:Search in 2015. BVGH met its 2014 objective of recruiting two new Funding Members.

Sixteen new Members joined WIPO Re:Search in 2014, bringing the total number of Members to 94 organizations from 26 countries. BVGH continues to focus on recruiting institutions located in the developing world. By the end of 2014, WIPO Re:Search included 28 developing world Members from15 countries.

NewMembers

Biomedical Research Institute

Central University of Ecuador*

Centre Pasteur du Cameroun*

Kineta, Inc

Merck KGaA

National Institute of Parasitic Diseases, Chinese CDC*

National University of Singapore

Noguchi Memorial Institute for Medical Research*

Salvensis

University of California, San Diego

University of Edinburgh

University of Ghana*

University of New South Wales

University of Yaoundé I*

Walter and Eliza Hall Institute of Medical Research

Washington University in St. Louis

* Developing world institution

Provider User

WIPO Re:Search Database Contribution - GlaxoSmithKline: Preparation of triazole derivatives as reversible inhibitors of bacterial methionine aminopeptidases (ID: 2063)

7

WIPO Re:Search Database Contribution - Eisai: Squalene synthase inhibitor (ID: 427)

Clinical

Pre-clinical

Optimization

Dose Response

Hits ID

Screening

Target Validation

Target ID

Discovery

Basic Research

Partnered project  initiatedPartnered project terminated

Partnered project cancelled

AZ -

LSTM

Lym

phat

ic �

laria

sis

Schi

stos

omia

sis

Alny

lam

- Ab

erys

twyt

hAZ

- UCS

F

Eski

tis In

stitu

te -

Swiss

TPH

GSK -

UCSF

GSK -

UCSF

MSD

- UCS

F

Alny

lam

- Ab

erys

twyt

h

NIPD -

U of I

bada

n

MSD

- UCS

F

Human

Afri

can

try

pano

som

iasis

GSK -

Seat

tle B

ioM

ed

AZ -

NEUAZ

- UCS

F

AZ -

U of D

unde

eEi

sai -

NEU

Leish

man

iasis

UCSF

- Sta

nfor

d

AZ -

Stan

ford

AZ -

UCSF

AZ -

UCSF

AZ -

U of D

unde

e

AZ -

NEU

UCSF

- NIH

Diarr

heal

dise

ase

P�ze

r - PA

TH &

UVM

AZ -

Anac

orP�

zer -

CW

HMP�

zer -

PATH

Sano

� - C

WHM

McG

ill -

UBCAZ

- M

cGill

& D

NDiAZ

- M

cGill

AZ -

UCSF

McM

aste

r - U

SF

Soil-

tran

smitt

ed

hel

min

thia

ses

Eski

tis In

stitu

te -

Swiss

TPH

KCCR

- St

anfo

rdLS

TM -

UCSF

Chag

as d

iseas

e

UBC -

McG

ill

AZ -

UCSF

AZ -

UCSF

AZ -

U of D

unde

eUBC

- M

cGill

AZ -

NEU

Dengu

e St

anfo

rd -

Calte

ch

NIH -

Emor

y

Novar

tis -

McM

aste

rP�

zer -

60P

P�ze

r - 6

0P

KU -

Kine

ta

CPC

- Sta

nfor

dEm

ory -

WRA

IR

Onc

hoce

rcia

sis

AZ -

LSTM

PATH

- KC

CR

Aber

ystw

yth

- U o

f Bue

aUBC

- U o

f Bue

a

Buru

li ul

cer

AZ -

Swiss

TPH

UBC -

Swiss

TPH

AZ -

Anac

or

Eski

tis In

stitu

te -

AZAZ

- iT

hem

baGSK

- CW

HMGSK

- NII

IDRI

- M

RC S

outh

Afri

caM

SD -

Emor

yNIH

- ID

RI

GSK -

IDRI

U of M

aurit

ius -

Em

ory &

NEU

Tube

rcul

osis

PATH

- Ca

ltech

UBC -

U of I

bada

n

Alny

lam

- Tu

lane

NEU -

CWHM

AZ -

LSTM

AZ -

LSTM

Eisa

i - U

of D

unde

e

Eisa

i - U

of D

unde

e

P�ze

r - M

cGill

U of L

agos

- NIP

D

Mal

aria

AZ -

UCSF

GSK -

NIIGSK

- UW

GSK -

UW

GSK -

NII

PATH

- U o

f Cal

gary

NEU -

NII

Eisa

i - L

STM

U of L

agos

- St

anfo

rd

GSK -

MIT

U of L

agos

- St

anfo

rd

U of L

agos

- Nov

artis

AZ -

NEU

UBC -

U of I

bada

n

NEU -

McG

ill

MSD

- W

EHI

KCCR

- NEU

Emor

y - C

alte

ch

Eisa

i - ID

RIEm

ory -

Kin

eta

KU -

Eisa

i

Neuro

cyst

icer

cosis

Oth

er

2014Communication Objectives

and Achievements

8

An integral responsibility of the Partnership Hub is to maintain Members’ awareness of its activities and to bolster participation in new

partnerships. Through the monthly WIPO Re:Search Partnership Hub Snapshot, BVGH continued to announce new agreements and new Members and to highlight Members’ assets described in the WIPO Re:Search Database. The Snapshot newsletter was sent to more than 1,100

readership of 29%.

Increasing awareness of the achievements of WIPO Re:Search within the greater global health community is also of critical importance. In 2014 BVGH presented WIPO Re:Search at 14 meetings

to develop publications, including two articles

journals.

Conference presentation

Neglected Disease Conferences: Anthelmintics - From Discovery to Resistance, USA

2014 British Society for Parasitology Spring Meeting, UK

14th Annual Quebec Molecular Parasitology Symposium, Canada

University of Washington Bioengineering Department Seminar, USA

Advances in Medicinal Plants Research in Ghana

Keystone Symposium: The Modes of Action of Vaccine Adjuvants, USA

1st Annual COST Action: Targeted Chemotherapy Towards Diseases Caused by Endoparasites, France

63rd Annual ASTMH Annual Meeting, USA

University of Washington Bioengineering Department Seminar, USA

2014 Joint International Tropical Medicine Meeting & Foodborne Parasitic Zoonoses, Thailand

Global Public Health and Industry Conferences: 7th EDCTP Forum - The Partnership Journey: New Horizon for Better Health, Germany

2014 Life Sciences Innovation Northwest, USA

2014 BIO International Convention, USA Talk/panel Poster

WIPO Re:Search Database Contribution - MSD: Long chain fatty acyl elongase (LCE) inhibitors against protozoa (ID: 1001)

9

2014Communication Objectives

and Achievements

WIPO Re:Search in the News “WIPO Re:Search Helps Take the ‘Neglected’ out of Tropical Diseases”, WIPO Media Center, Jan. 2014

“Collaboration – Researcher from Nigeria Talks about Malaria and WIPO Re:Search”, Nigerian Law Intellectual Property Watch, Feb. 2014

Global Intellectual Property Center (GIPC) Interview, Francis Gurry, Feb. 2014

“2014 Special 301 Report” Best Intellectual Property Rights Practices by Trading Partners

Representative, Apr. 2014

“Ebola Needs a New Model of Drug Development”, The Seattle Times, Aug. 2014

“Emerging and Reemerging Neglected Tropical Diseases: a Review of Key Characteristics, Risk Factors, and the Policy and Innovation Environment”, Clinical Microbiology Reviews, Oct. 2014

“Neglected Diseases Research Gets a Boost as Merck KGaA Joins Consortium”, The Pharmaceutical Journal, Dec. 2014

10

Communication“WIPO Re:Search: Catalyzing Collaborations to Accelerate Product Development for Diseases of Poverty”Chemical ReviewsImpact factor: 45.7Featured collaborations: NIH + IDRI: natural products for tuberculosis AZ + Eskitis Institute: natural products for tuberculosis GSK + NII: kinase inhibitors for tuberculosis GSK + NII: kinase inhibitors for blood-stage malaria P�zer + PATH: data for drug repurposed for diarrheal disease

“WIPO Re:Search: Accelerating Anthelmintic Development Through Cross-Sector Partnerships”International Journal of Parasitology: Drugs and Drug ResistanceImpact factor: 2.5Featured collaborations: Swiss TPH + Eskitis Institute: natural products for schistosomiasis & soil-transmitted helminthiases (STH) McGill + AZ + Eskitis Institute: high-throughput screens for STH using C. elegans University of Buea + UBC: activity-guided fractionation of anti- onchocercal natural products Stanford + TBRI: hosting of Olfat Hammam UCSF + KNUST: hosting of Christian Agyare Novartis + University of Buea: hosting of Fidelis Cho-Ngwa

11

2014 and 2015Conclusions and

Objectives

12

BVGH met and exceeded all program objectives in 2014: Established 37 new agreements

Recruited 14 new “targeted” User Members

Recruited two new Funding Members

Continued communication activities

BVGH objectives and deliverables for 2015 include: Establish 20 new agreements*

Recruit at least eight “targeted” User Members and two Funding Members

Continue activities to increase awareness of WIPO Re:Search

Develop and implement surveys of Members’ expectations of WIPO Re:Search and the

Members.

*BVGH has begun implementing a more strategic approach to partnering. Partnering activities are now divided into three categories: new collaborations, advancing collaborations, and

strategic interests. BVGH will continue to facilitate collaborations between Members as it has in the past. However, in addition to these “standard” collaborations, BVGH will work with each Sponsor Member to establish collaborations that meet its particular strategies or interests,

disease or partner. In addition to facilitating

to encourage the continued advancement of previously-established WIPO Re:Search partnerships. BVGH will work with these partnerships’ Members to identify additional Members with the expertise needed to move a project forward.

WIPO Re:Search Database Contribution - P�zer: Nucleic acid coated-particles for delivery of

nucleic acid-based vaccines (ID: 941)

BIO Ventures for Global Health 401 Terry Avenue North, Seattle, WA 98109, USAEmail: info@bvgh.org Website: http://www.bvgh.org

Developed in cooperation with our Sponsors: